

Neuropsychological Features of Microbleeds and Cortical Microinfarct Detected by High Resolution Magnetic Resonance Imaging

Yukito Ueda^a, Masayuki Satoh^{a,*}, Ken-ichi Tabei^{a,b}, Hirotaka Kida^a, Yuichiro Ii^b, Masaru Asahi^b,
Masayuki Maeda^c, Hajime Sakuma^c and Hidekazu Tomimoto^{a,b,*}

^a*Department of Dementia Prevention and Therapeutics, Graduate School of Medicine, Mie University,
Mie, Japan*

^b*Department of Neurology, Graduate School of Medicine, Mie University, Mie, Japan*

^c*Department of Radiology, Graduate School of Medicine, Mie University, Mie, Japan*

Handling Associate Editor: Jae-Hong Lee

Accepted 1 April 2016

Abstract.

Background: Lobar microbleeds (MBs) and cortical microinfarct (CMI) are caused by cerebral amyloid angiopathy in the elderly and increase in number in Alzheimer's disease.

Objective: The aim of this study is to elucidate the effects of lobar MBs and CMIs on cognitive function.

Methods: The subjects were outpatients who visited memory clinic of Mie University Hospital. Among 120 subjects, 109 patients fulfilled the inclusion criteria. We quantitatively estimated MBs and CMIs using double inversion recovery and 3D FLAIR images of 3T MRI. Neuropsychological assessments included intellectual, memory, constructional, and frontal lobe function.

Results: Of the 109 patients, MBs and CMIs were observed in 68 (62%) and 17 (16%) subjects, respectively. Of the 68 patients with MBs, lobar MBs were found in 28, deep MBs in 8 and mixed MBs in 31. In each age group, the number of MBs increased in patients with CMI (CMI+ group) than those without CMI (CMI- group), and MBs and CMIs additively decreased MMSE scores. In psychological screens, the MBs+ group with more than 10 MBs showed significantly lower scores of category- and letter-WF than MB- group. The CMI+ group showed significantly worse scores than CMI- group in Japanese Raven's coloured progressive matrices, Trail Making Test-A, category- and letter-word fluency and copy and drawing of figures.

Conclusion: Lobar MBs and CMIs in the elderly frequently coexisted with each other and additively contributed to cognitive impairment, which is mainly predisposed to frontal lobe function.

Keywords: Bleeding, cerebral amyloid angiopathy, dementia, infarct, magnetic resonance imaging, neuropsychological test

INTRODUCTION

The main pathological features of small vessel disease (SVD) contain microbleeds (MBs), lacunar infarctions, white matter lesions (leukoaraiosis), and cortical microinfarcts (CMIs) [1]. These MBs

*Correspondence to: Masayuki Satoh and Hidekazu Tomimoto, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. Tel.: +81 059 231 5104; Fax: +81 059 231 5082; E-mails: bruckner@clin.medic.mie-u.ac.jp (MS); tomimoto@clin.medic.mie-u.ac.jp (HS)

are characterized by small (less than 5 or 10 mm in diameter), homogeneous, and round foci of low signal intensity [2] and are distributed in the lobar (cortical and subcortical region) region or alternatively, the deep/infratentorial region including the basal ganglia, thalamus, and infratentorial structures [2]. A close correlation has been shown between deep/infratentorial MBs and hypertensive SVD, and also between lobar MBs and cerebral amyloid angiopathy (CAA) [3].

On the other hand, CMIs are defined as sharply demarcated microscopic regions of cellular death or tissue necrosis [4] and remained invisible in conventional magnetic resonance imaging (MRI) [5]. In pathological specimens, CMIs are distributed predominantly in the parietal and occipital lobes [6, 7] and watershed regions [8]. They are encountered in 16 to 46% of elderly people in any cause of death [4] or 33% in cognitively normal elderly people [9]. CMIs have been attributed to CAA and found frequently in Alzheimer's disease (AD) brains [6, 10]. More Recently, van Rooden et al. have reported that CMIs are found more numerous in AD compared to control subjects, and have been negatively correlated to cognitive function in clinicopathological observations [11]. More recently, van Veluw et al. [12] has reported worse clinical correlates in memory clinic patients with CMI, but it remains uncertain whether difference of detection methods, ethnic populations, and degree of other small vessel disease may affect negative relationship between CMI and cognitive function.

We have reported a novel method for *in vivo* detection of CMIs using 3T MRI [13], and suggested that CMIs and lobar MBs share a common etiology in dementia patients. The detection of CMIs by high resolution MRI has been further reported using 7T MRI [11, 14] and 3 T MRI [15]. The purpose of the present study is to clarify the correlation of lobar MBs, CMIs, and cognitive dysfunction and further, neuropsychological characteristics of patients with these amyloid-related vasculopathy.

MATERIALS AND METHODS

Subjects

We prospectively registered 120 patients who consulted the memory clinic of our hospital and registered for this study with high-resolution 3T MRI and screening with neuropsychological tests. All procedures followed the Clinical Study Guidelines

of the Ethics Committee of Mie University Hospital and were approved by the internal review board. A complete description of all procedures was provided to the patients, and written informed consent was obtained from them or their caregivers. Every patient was examined comprehensively by neurologists with sufficient experience in examining patients with dementia. We collected data from the patients who fulfilled the following inclusion criteria: 1) consulted with the Memory Clinic of our hospital from October 2011 to June 2013, 2) had a neuroimaging examination using 3T-MRI, 3) had completed neuropsychological assessments, and 4) had blood laboratory examination. Exclusion criteria were as follows: The patients 1) declined or could not be examined by MRI, 2) declined neuropsychological assessments, 3) were diagnosed with treatable dementia, and 4) had normal cognitive function.

All diagnoses were based on pre-established criteria: For AD, fulfilling the criteria for probable AD of the National Institute of Neurologic Disorders and Stroke/Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) [16]; for vascular dementia (VaD), fulfilling the criteria for probable VaD of the National Institute of Neurologic Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) [17]; for mild cognitive impairment (MCI), fulfilling the general criteria of the International Working Group on MCI [18]; for dementia with Lewy bodies (DLB), fulfilling the clinical criteria of the consortium on DLB [19]; for frontotemporal lobar degeneration, fulfilling the Lund-Manchester criteria for behavioral variant frontotemporal dementia, semantic dementia, or progressive nonfluent aphasia [20]; for CAA, represented by Charidimou [1]; and for AD with cerebrovascular disease by Bruandet [21].

Laboratory tests included thyroid-stimulating hormone, free thyroid 3, free thyroid 4, treponema palladium hemagglutination, vitamin B1, vitamin B12, folic acid, thyroglobulin autoantibody, and thyroid peroxidase.

MR imaging protocol

MR imaging protocol was the same protocol of Li et al. [13]. Briefly, MRI studies were performed with a 3T MR unit (Achieva, Philips Medical System, Best, the Netherlands) using an 8- or 32- channel phased-array head coil. We used double inversion




Fig. 1. Representative images of MBs and CMI in a patient with Alzheimer's disease. Arrows in (A) indicate MBs and a circle indicates location of CMI. Arrows in (B, C) indicate CMI.

recovery (DIR) and 3D-fluid attenuated inversion recovery (FLAIR) images, to detect CMI *in vivo*. Axial DIR imaging was performed using two different inversion pulses. The long inversion time and the short inversion time were defined as the intervals between the 180° inversion pulse and the 90° excitation pulse, respectively, which had been optimized for human brain imaging and were provided by the vendor.

Details of the 2D and 3D DIR protocol were as follows: Field of view, 230 mm; matrix, 320 × 256 (512 × 512) after reconstruction; in-plane resolution, 0.45 mm × 0.45 mm; section thickness, 3 mm with no intersection gap; no parallel imaging; repetition time (ms)/echo time (ms), 15,000/28; long inversion time (ms)/short inversion time (ms), 3,400/325; number of signals acquired, two; and acquisition time, 4 min 30 s for 2D, field of view, 250 mm; matrix, 208 × 163 (256 × 256) after reconstruction; in plane resolution, 0.98 mm × 0.98 mm; section thickness, 0.65 mm with over contiguous slice; TSE factor 173; repetition time (ms)/echo time (ms), 5,500/247; long inversion time (ms)/short inversion time (ms), 2,550/450; number of signals acquired, two; and acquisition time, 5 min 13 s for 3D.

The details of susceptibility-weighted imaging (SWI) were follows: Field of view, 230 mm; matrix, 320 × 251 (512 × 512 after reconstruction; in-plane resolution, 0.45 mm × 45 mm); section thickness, 0.5 mm with over contiguous slice; repetition time (ms)/echo time (ms), 22/11.5 (in-phase), 33 (shifted);

number of signals acquired, one; flip angle 20° and acquisition time, 5 min 45 s. 3D FLAIR imaging was obtained in a sagittal direction, and then the axial and coronal images were reconstructed. The details of 3D FLAIR were as follows: Field of view, 260 mm; matrix, 288 × 288 (364 × 364 after reconstruction; in-plane resolution, 0.68 × 0.67 mm); section thickness, 1 mm with 0.5 mm overlap; no parallel imaging; repetition time (ms)/echo time (ms), 6,000/400; inversion time, 2,000 ms; number of signals acquired, two; and acquisition time, 5 min 12 s.

Evaluation of CMI and MBs on MR imaging

MBs were defined on SWI images as small (<10 mm), homogeneous, round foci [2] (Fig. 1A), and were assessed by 2 separate raters, who were blinded to diagnosis followed by a consensus reading. CAA was defined on the basis of the location and presence of MBs according to the Boston criteria [22]. MBs were counted throughout the brain and categorized as 'deep' in the basal ganglia/thalamus (including the internal and external capsule), 'infratentorial' (brain stem and cerebellum), and 'lobar' (cerebral cortex and subcortical and periventricular white matter) regions. If the MBs were observed at both lobar and deep regions, the subject was classified as 'mixed MBs'. Lobar MBs were subgrouped as frontal, temporal, parietal, and occipital. When at least one small hypointense focus was

194 detected, the region or area of the brain was defined
195 as MBs-positive.

196 CMI was defined as small cortical hyperintense
197 lesions not contiguous to white matter hyperinten-
198 sities, with a maximum diameter of 5 mm, and a
199 round or elliptical shape, not connected to other struc-
200 tures (tubular shapes, white matter hyperintensities,
201 or white matter tracts) (Fig. 1B, C). CMI was inde-
202 pendently assessed on DIR images by two separate
203 raters. Only cortical or juxtacortical lesions with the
204 same or a higher intensity than the relatively hyperin-
205 tense outer cortex layer were scored. The cortical and
206 juxtacortical location was confirmed in sagittal, cor-
207 onal, and transverse directions. If the location could
208 not be determined exactly on the DIR images, the
209 location was determined on FLAIR images.

210 For the detection of CMIs, we utilized both the
211 FLAIR and DIR, based on the reported literatures
212 which investigated the cortical lesion of patients
213 with multiple sclerosis [e.g., 23–26]. The literature
214 showed that the DIR was useful to detect the cortical
215 lesion of multiple sclerosis patients. In the present
216 study, we judged the existence of CMI only when the
217 lesion was detected by both FLAIR and DIR image
218 on an ultrahigh-field MR scanner. That means our
219 criterion is relatively tight.

220 *Neuropsychological assessments*

221 The following tests were performed: For intellec-
222 tual ability, Mini-Mental State Examination (MMSE)
223 and Japanese Raven's Coloured Progressive Matrices
224 (RCPM) [27]; for memory, Rivermead Behav-
225 ior Memory Test (RBMT) [28]; for visuospatial
226 function, the construction test (Copy and Drawing of
227 cube and Necker cube) [29]; for frontal lobe function,
228 Word fluency (WF: Category Cue task, animal; Letter
229 Cue task, ta, te, sa, ka), and Trail making test-A/-B
230 (TMT-A, TMT-B).

231 *Statistical analyses*

232 Statistical analyses were performed with the Sta-
233 tistical Package for the Social Sciences, Version 20
234 (SPSS, Chicago, Illinois). Group comparisons with
235 respect to the number of CMI and MBs were per-
236 formed by using independent *t*-tests for continuous
237 data, and chi-square tests for dichotomous data, and
238 Mann-Whitney U tests for nonparametric data. Dif-
239 ferences of $p=0.05$ were considered statistically
240 significant.

241 **RESULTS**

242 *Study population*

243 Consequently, 120 patients have been registered
244 for this study and 109 patients fulfilled the inclusion
245 criteria (Fig. 2). The distribution of number of MBs
246 has the border at 10, therefore, we used 10 as a classi-
247 fication standard of MBs (Supplementary Fig. 1). Of
248 the 109 patients, 47 had MBs from 1 to 9, and 21 had
249 10 or more. All 28 patients with lobar MBs had less
250 than 10 MBs, whereas 21 of 31 (67.7%) patients with
251 mixed MBs had 10 or more MBs (Fig. 2). In the both
252 DIR and 3D FLAIR images, CMIs were observed in
253 17 patients, and, among them, 9 patients belonged
254 to the group of over 10 MBs and 3 to the group of
255 1–9 MBs (Fig. 3). There were 5 patients with CMI
256 but without MBs, and this finding was dissociated
257 from our previous research showing that all patients
258 with CMI accompanied MBs [13]. We performed the
259 statistical analyses about the prevalence and associ-
260 ation of MBs and CMI by diagnosis (Supplementary
261 Table 1). The results of multiple comparison showed
262 that numbers of MBs of CAA were significantly
263 greater than AD ($p=0.015$). The result of numbers of
264 CMI showed no significant differences in diagnosis.
265 We analyzed the lobar distribution of MBs and CMIs
266 (Supplementary Table 2a, b). There were significant
267 differences between frontal and parietal on MBs as a
268 result of multiple comparison ($p<0.001$).

269 We performed the analysis of comparing between
270 CMIs+/MBs+ and CMIs+/MBs-. There was no
271 significant difference on any neuropsychological
272 assessments (Supplementary Table 3). However,
273 analysis of comparing between CMIs+/MBs- and
274 CMIs-/MBs- showed significant differences on age,
275 RCPM time, and WF (Category) (Supplementary
276 Table 4). Furthermore, we performed the generalized
277 linear model with the negative binomial distribution
278 analysis about the CMI and MBs for the cogni-
279 tion (Supplementary Tables 5 and 6). These results
280 showed that CMI significantly have effect on TMT-A
281 and WF (letter).

282 *MBs*

283 Between the MBs+ and MBs- groups, there
284 were significant difference in the frequency of edu-
285 cation ($p=0.003$) and hyperlipidemia ($p=0.027$).
286 Neuropsychological assessment showed a decreased
287 score in category- ($p=0.004$) and letter-WF
288 ($p=0.004$) and increased score in copy-Construction




Fig. 2. Flow diagram of inclusion, exclusion and MRI diagnosis of the 109 subjects. The digits in the parentheses show the number of the patients. + and - shows the positive and negative, respectively: AD, Alzheimer's disease; CAA, cerebral amyloid angiopathy; CMI, cortical microinfarct; CVD, cerebrovascular disease; D, deep; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; I, infratentorial; L, lobar; M, mixed; MBs, microbleeds; MCI, mild cognitive impairment; PPA, primary progressive aphasia; SD, semantic dementia.

289 ($p=0.047$) in the MBs+ group (Table 1). Accord- 300
 290 ing to the number of MBs, there were significant 301
 291 differences exclusively in category- and letter-WF 302
 292 between the MBs- group, the MBs+ group from 1 303
 293 to 9 and 10 or more. In these groups, the number of 304
 294 words for category were 11.4 ± 3.7 , 9.5 ± 4.1 , and 305
 295 8.0 ± 3.4 , respectively, whereas those for letter were 306
 296 5.7 ± 2.0 , 4.9 ± 2.0 , and 3.9 ± 1.6 , respectively. The 307
 297 MBs+ group with more than 10 MBs showed sig- 308
 298 nificantly lower scores of category- and letter-WF 309
 299 than MB- group. From the standpoint of MBs loca- 310
 300 tion, there were significant differences exclusively 311

in category- and letter-WF between the lobar, deep 301
 and mixed MBs groups. The number of words for 302
 category were 9.8 ± 4.4 , 8.1 ± 4.1 , and 8.6 ± 3.4 , 303
 respectively, whereas those for letter were 4.9 ± 2.1 , 304
 4.7 ± 1.3 , and 4.4 ± 1.9 , respectively. The difference 305
 between MBs- and mixed type distribution of MBs 306
 was in category-WF ($p=0.04$). The results of TMT- 307
 A/B of our subjects were prolonged compared to 308
 normal subjects. The normal range of TMT-A and 309
 B are as follows: A; 70-74 year-old 117.3 ± 30.8 , 310
 75-79 y.o. 123.1 ± 30.5 , B; 70-74 y.o. 167.2 ± 46.9 , 311
 and 75-79 y.o. 179.5 ± 48.4 . Both the MBs- (TMT-A 312




Fig. 3. Distribution of MBs and CMI in the 109 patients.

197 ± 89, -B 301 ± 142) and MBs+ groups (TMT-A 233 ± 132, -B 280 ± 130) were impaired. We may say that, because the TMT is more difficult than WF, the discrepancy between them appeared.

CMI

Of the 17 with CMI, there were 9 patients with mixed MBs, 2 with lobar MBs, and 1 with deep MBs. Between the CMI+ and CMI- groups, there was significant difference in age ($p < 0.001$). Neuropsychological assessment showed significantly worse scores in RCPM ($p = 0.025$), TMT-A ($p = 0.023$), category- ($p = 0.05$) and letter-WF ($p = 0.006$), and

drawing of figures ($p = 0.034$) (Table 2). The average number of MBs was 51.7 ± 137.2 in the CMI+ group and 6.0 ± 16.1 in the CMI- group, being more numerous in the CMI+ group ($p = 0.027$). With advancing ages, there were trends for numerical increase of MBs only when CMIs coexisted (Fig. 4A). About the relationship between MMSE scores, MBs, and CMIs, the MMSE score was significantly lower in the CMI+ group than the CMI- group ($p = 0.01$) exclusively in the MBs+ group (10 or more) (Fig. 4B). Among the subjects with mixed MBs distribution, the CMI+ group showed significantly worse scores of MMSE ($p = 0.002$), TMT-A ($p = 0.008$), and category- and letter-WF ($p = 0.004$; $p < 0.001$) (Table 3).

Stroke, white matter lesions, atrophy

There were three patients with cerebral infarct in the present study. The results of neuropsychological assessments between presence and absence of cerebral infarct did not show any significant differences (Supplementary Table 7). Regarding lacunar infarction, patients with lacunar infarction were significant worse than those patients without in the RCPM score, RBMT (SPS, SS), TMT-A, and WF (category) (Supplementary Table 8). Assessment of white matter lesion using Fazekas scale (PVH) showed that value of scale was more severe; value of MMSE, RCPM-score, TMT-A, and WF (category and letter) were worse (Supplementary Table 9). Assessment of white

Table 1
Characteristics and neuropsychological assessments of the patients with or without MBs or CMI

	MBs (+) n=68	MBs (-) n=41	p-value
<i>Demographics</i>			
Age	76.4 (6.5)	74.0 (7.3)	0.083
Male	26 (38.2%)	16 (39.0%)	0.16
Education (years)	10.2 (3.1)	11.8 (2.2)	0.003*
Hypertension	43%	37%	0.53
Hyperlipidemia	9%	24%	0.027*
Diabetes mellitus	10%	12%	0.76
<i>Neuropsychological assessments</i>			
MMSE	22.3 (4.2)	22.9 (4.4)	0.49
RCPM			
Score	24.8 (5.8)	25.2 (5.8)	0.76
Time (s)	528 (263)	503 (279)	0.48
RBMT			
SPS	7.2 (5.8)	6.9 (6.2)	0.64
SS	2.6 (2.6)	2.5 (2.9)	0.71
TMT			
A (s)	233 (132)	197 (89)	0.24
B (s)	280 (130)	301 (142)	0.55
WF			
Category	9.0 (3.9)	11.4 (3.7)	0.004*
Letter	4.6 (1.9)	5.7 (2.1)	0.004*
Construction			
Copy	2.6 (0.6)	2.8 (0.7)	0.047*
Drawing	2.2 (1.0)	2.4 (0.8)	0.19

MBs, Microbleeds; MMSE, Mini-Mental State Examination; RBMT, Rivermead Behavior Memory Test; RCPM, Raven's Colored Progressive Matrices; TMT, Trail-Making Test; WF, word fluency.

Table 2
Characteristics and neuropsychological assessments of the patients with or without CMI

	CMI (+) n=17	CMI (-) n=91	p-value	
<i>Demographics</i>				
Age	80.0 (2.6)	74.7 (7.2)	<0.001*	
Male	9 (52.9%)	33 (35.9%)	<0.001*	
Education (years)	11.0 (3.3)	10.7 (2.8)	0.97	
Hypertension	41%	41%	0.97	
Hyperlipidemia	18%	14%	0.72	
Diabetes mellitus	18%	10%	0.35	
<i>Neuropsychological assessments</i>				
MMSE	20.9 (4.2)	22.8 (4.3)	0.087	
RCPM	Score	22.1 (6.2)	25.5 (5.6)	0.025*
	Time (s)	540 (202)	513 (281)	0.3
RBMT	SPS	6.5 (5.2)	7.2 (6.1)	0.84
	SS	2.0 (2.1)	2.6 (2.8)	0.62
TMT	A (s)	289 (141)	204 (105)	0.023*
	B (s)	235 (118)	293 (136)	0.43
WF	Category (/min)	8.2 (4.7)	10.3 (3.7)	0.05*
	Letter (/min)	3.8 (2.0)	5.3 (1.9)	0.006*
Construction	Copy	2.6 (0.5)	2.7 (0.7)	0.11
	Drawing	1.8 (1.0)	2.3 (0.9)	0.034*

CMI, cortical microinfarct; MMSE, Mini-Mental State Examination; RBMT, Rivermead Behavior Memory Test; RCPM, Raven's Colored Progressive Matrices; TMT, Trail-Making Test; WF, word fluency.

Table 3
Comparison of neuropsychological assessments between patients with or without CMIs among those with mixed MBs

	CMI (+), n=9	CMI (-), n=21	p-value	
<i>Demographics</i>				
Age	78.7 (2.9)	77.2 (4.5)	0.42	
Male	3 (33.3%)	9 (42.9%)	0.15	
Education (years)	9.3 (2.0)	10.4 (3.1)	0.41	
Hypertension	44%	48%	0.9	
Hyperlipidemia	0%	10%	0.69	
Diabetes mellitus	11%	5%	0.79	
<i>Neuropsychological assessments</i>				
MMSE	18.6 (3.1)	23.4 (3.7)	0.002*	
RCPM	Score	21.6 (4.8)	25.0 (5.9)	0.24
	Time (s)	552 (216)	584 (326)	0.89
RBMT	SPS	4.4 (3.3)	8.4 (6.2)	0.14
	SS	1.0 (0.9)	3.2 (2.9)	0.09
TMT	A (s)	324 (144)	184 (86)	0.008*
	B (s)	407	250 (107)	0.46
WF	Category (/min)	6.1 (2.6)	9.9 (3.1)	0.004*
	Letter (/min)	2.8 (1.3)	5.2 (1.5)	<0.001*
Construction	Copy	2.4 (0.5)	2.8 (0.4)	0.18
	Drawing	1.4 (1.0)	2.2 (0.8)	0.056

MBs, Microbleeds; CMI, cortical microinfarct; MMSE, Mini-Mental State Examination; RBMT, Rivermead Behavior Memory Test; RCPM, Raven's Colored Progressive Matrices; TMT, Trail-Making Test; WF, word fluency.

353 matter lesion using Fazekas scale (DWMH) showed
354 that value of scale was more severe; value of RCPM-
355 time, RBMT (SPS, SS), and TMT-A were worse
356 (Supplementary Table 10). Regarding atrophy, Evans
357 index showed that there was no significant differ-
358 ence between right and wrong score (Supplementary
359 Table 11).

DISCUSSION

360
361 The findings of the present study were summarized
362 as follows: i) among 109 subjects who fulfilled the
363 inclusion criteria, MBs and CMIs were observed in
364 68 and 17 subjects, respectively; ii) of the 68 subjects
365 with MBs, there are those with 28 lobar MBs (41%),
366




Fig. 4. Relationship between frequency of MBs and CMIs in each age (A) and their contribution to MMSE scores (B).

366 9 deep/infratentorial MBs (13%), and 31 mixed MBs
 367 (46%); iii) there is a numerical increase of MBs in
 368 CMI+ group especially in older ages; iv) in compar-
 369 ison between CMI+ and CMI- groups with mixed
 370 MBs, the former showed significantly worse scores
 371 in RCPM (score), TMT-A, category- and letter-word
 372 fluency, and copy and drawing of figures. The rel-
 373 atively small number of MBs at deep/infratentorial
 374 region may be attributable to the cohort specificity of
 375 memory clinic, which mostly consists of MCI and AD
 376 patients. It is noteworthy that the rate of the subjects
 377 with hyperlipidemia was significantly higher in the
 378 MBs- group, as compared to the MBs+ group, and
 379 may supplement inverse association between serum
 380 cholesterol and hemorrhagic stroke, especially with
 381 hypertension [30]. The subjects of the present study
 382 were quite different from our previous report [13], but
 383 the prevalence of CMI and MBs of both reports are
 384 similar ([13], CMI 13%, MBs 54%; the present study,
 385 CMI 16%, MBs 62%). The main difference of the
 386 results of the previous and the present study was that,
 387 in the present study, there were some subjects who
 388 possessed only CMIs without MB. In the previous
 389 report, all patients who possessed CMI also showed
 390 MBs. The reason for this difference might be caused
 391 by the difference of the clinical department. That is,
 392 the subjects of Ii's report [13] were recruited from
 393 outpatients who consulted with the Department of
 394 Neurology, whereas those of the present study were
 395 from a memory clinic.

396 The neuropsychological data have revealed that the
 397 MBs and CMIs contributed additively to cognitive
 398 impairment. The association between MB and cog-
 399 nition has already been shown by previous studies
 400 (e.g., [31–33]) and our results replicate these find-
 401 ings. Although analysis of the comparison between
 402 CMIs+/MBs- and CMIs+/MBs- showed significant
 403 differences on age, RCPM time, and WF (Category),
 404 analysis of the comparison between CMIs+/MBs+
 405 and CMIs+/MBs- showed no significant difference
 406 on any neuropsychological assessments. Therefore,
 407 we may say that CMIs are a risk for cognitive
 408 dysfunction. There are several studies revealing a
 409 deteriorative effect of MBs on cognitive function.
 410 In population-based studies using SWI, MBs were
 411 detected in about 40% of people over 80 years of age
 412 [34] and correlated with lower scores on the MMSE
 413 [35]. In the Rotterdam Scan Study on non-demented
 414 community-resident people, more than five MBs
 415 revealed a relationship with decline in all cognitive
 416 function except for memory [33]. In the IAGES-
 417 Reykjavik study, multiple deep MBs were related
 418 to impairment of processing speed and executive
 419 function [31]. All these data indicate that MBs are
 420 related to executive dysfunction, the deterioration of
 421 psychomotor speed, and attention deficit [1]. The
 422 present study further confirmed a positive correlation
 423 between the number of MBs and frontal lobe dys-
 424 function. The relationship between MBs and frontal
 425 dysfunction was already reported in the literature
 426 (e.g., frontal-executive impairment: [36]; attention:
 427 [37]). The underlying mechanisms of the pathologi-
 428 cal association between SVD and frontal dysfunction
 429 are unknown. However, for example, Van Norden
 430 et al. [37] discussed that histopathologic studies have
 431 shown that the presence of MB indicates widespread
 432 damage of arterioles by hypertension or by amy-
 433 loid deposition as well as surrounding gliosis or even
 434 frank necrosis or infarction, resulting in microstruc-
 435 tural damage of the surrounding white matter [38, 39].
 436 In this way, MBs may disrupt white matter tracts rel-
 437 evant for cognitive function leading to damage to the
 438 neural networks superimposed to the effects of often
 439 co-occurring WML and lacunar infarcts.

440 On the contrary, it remains to be clarified whether
 441 CMIs are risk for dementia [4] based on the following
 442 reasons. First, evidence for the positive correlation
 443 has been based on retrospective clinic-pathological
 444 comparison and is endowed with anonymity [40].
 445 Second, the frequency of CMIs has been shown
 446 to be relatively high even in non-demented people,
 447 and lastly, CMIs may accompany other vascular

448 lesions such as macro-infarction, lacunar infarction,
449 and white matter lesions.

450 We applied exactly the same method by Ii et al.,
451 which makes feasible a sensitive detection of CMIs
452 by 3D-FLAIR image and further identified cortical
453 localization by DIR using 3D MRI [13] in the present
454 study. It is reasonably concluded that the CMIs induce
455 cognitive impairment, particularly related to frontal
456 lobe dysfunction. In the elderly, CMIs have been
457 mainly attributed to CAA [6]. To some extent, CAA is
458 always present in AD brains and therefore, CMIs can
459 be frequently observed in AD brains, especially in
460 association with CAA [41]. As for the mechanisms
461 of cognitive dysfunction, CMIs may directly dam-
462 age the surrounding structures [42], but it is more
463 likely that CMIs may represent an advanced stage
464 of small vessel changes and its related blood-brain
465 barrier disintegration and brain atrophy, because the
466 observed finding for CMIs is only the tip of ice-
467 berg found in pathological specimens. In concert with
468 this mechanism, Raman et al. reported that microin-
469 farcts accelerated brain atrophy independent of AD
470 pathology [43].

471 CMIs have been causatively related to CAA in
472 demented patients. However, in the present study,
473 CMIs frequently coexisted with mixed and multiple
474 MBs, but not with pure lobar MBs. It is presumed
475 that association of CMIs with mixed MBs represents
476 relatively advanced SVD, which comprises two sub-
477 types of SVD; i.e., hypertensive SVD and CAA with
478 concordant progression [44]. This hypothesis appears
479 to be underscored by a recent study in which both
480 hypertensive SVD and CAA contributed to the patho-
481 genesis of lobar MBs, at least in subjects with mixed
482 MBs [45].

483 A large body of evidence has demonstrated
484 correlation between frontal lobe dysfunction and
485 hypertensive SVD [46, 47] and recently between
486 those and CAA [48]. In the present study, CMIs,
487 which may represent amyloid-related vasculopa-
488 thy, coexisted frequently with mixed MBs, thereby
489 suggesting that the both subtypes of SVD have con-
490 tributed to impairment of executive function and word
491 fluency.

492 This study has several limitations due to a relatively
493 low detection rate of CMIs which was shown to be 17
494 of 109 (16%) in demented population. The rate was
495 lower than 6 of 15 (40%) in demented brains with
496 7T MRI [14] and 24% (ranged between 3–43%) in
497 pathological specimens [49], but higher than 6% in
498 non-demented elderly patients with systolic hyper-
499 tension with 3T MRI [15]. The low detection rate

of CMIs made it difficult to accurately identify dis- 500
tribution of the whole CMIs and their contribution 501
to cognitive impairment. Second, the effect of CMIs 502
without MBs remains unclear. Among the 41 subjects 503
without MBs, only five subjects possessed CMIs and 504
were not suitable for statistical analysis. Lastly, the 505
differential effect of CMIs was not identified among 506
a variety of dementing illness, because most of the 507
patients were categorized as having AD. 508

509 CONCLUSION

510 We carried out a series experiment using 3T MRI to
511 memory clinic outpatients, in order to investigate the
512 effects of MBs and CMIs on cognitive function. More
513 MBs caused more severe cognitive impairment. The
514 presence of CMIs might be an additional risk factor
515 for dementia particularly of frontal lobe dysfunction.
516 New imaging technique using 3T MRI combined with
517 3D FLAIR and DIR images is a useful tool to detect
518 CMIs in clinical setting.

519 ACKNOWLEDGMENTS

520 We would like to thank the following persons for
521 their kind contributions to this study: Kana Matsuda
522 in the department of rehabilitation, and Shin-ichi
523 Takase in the department of radiology.

524 Authors' disclosures available online (<http://j-alz.com/manuscript-disclosures/15-1008r1>). 525

526 SUPPLEMENTARY MATERIAL

527 The supplementary material is available in the
528 electronic version of this article: <http://dx.doi.org/10.3233/JAD-151008>. 529

530 REFERENCES

- 531 [1] Charidimou A, Werring DJ (2012) Cerebral microbleeds
532 and cognition in cerebrovascular disease: An update. *J Neu-
533 rol Sci* **322**, 50-55.
- 534 [2] Uetani H, Hirai T, Hashimoto M, Ikeda M, Kitajima
535 M, Sakamoto F, Utsunomiya D, Oda S, Sugiyama S,
536 Matsubara J, Yamashita Y (2013) Prevalence and topog-
537 raphy of small hypointense foci microbleeds on 3T
538 susceptibility-weighted imaging in various types of
539 dementia. *AJNR Am J Neuroradiol* **34**, 984-989.
- 540 [3] Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam
541 RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch
542 MP, Rosand J, Johnson KA, Viswanathan A, Salat DH,
543 Greenberg SM (2010) Spatial relation between microbleeds
544 and amyloid deposits in amyloid angiopathy. *Ann Neurol* **68**,
545 545-548.

- 546 [4] Smith EE, Schneider JA, Wardlaw JM, Greenberg SM
547 (2012) Cerebral microinfarcts: The invisible lesions. *Lancet*
548 *Neurol* **11**, 272-282. 611
- 549 [5] Gouw AA, Seewann A, van der Flier WM, Barkhof F,
550 Rozenmuller AM, Scheltens P, Geurts JJ (2011) Heterogene-
551 ity of small vessel disease: A systematic review of MRI and
552 histopathology correlations. *J Neurol Neurosurg Psychiatry*
553 **82**, 126-135. 612
- 554 [6] Okamoto Y, Ihara M, Fujita Y, Ito H, Takahashi R, Tomimoto
555 H (2009) Cortical micro infarcts in Alzheimer's disease and
556 subcortical vascular dementia. *Neuroreport* **20**, 990-996. 613
- 557 [7] Soontornniyomkij V, Lynch MD, Mermash S, Pomakian
558 J, Badkoobehi H, Clare R, Vinters HV (2010) Cerebral
559 microinfarcts associated with severe cerebral beta-amyloid
560 angiopathy. *Brain Pathol* **20**, 459-467. 614
- 561 [8] Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA,
562 Lee S, Wang C, Verghese J (2010) Contribution of vascular
563 pathology to the clinical expression of dementia. *Neurobiol*
564 *Aging* **31**, 1710-1720. 615
- 565 [9] Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz
566 JB, Montine KS, Jack CR, Kaye J, Lim K, Larson EB, White
567 L, Montine TJ (2011) Ecology of the aging human brain.
568 *Arch Neurol* **68**, 1049-1056. 616
- 569 [10] Haglund M, Passant U, Sjöbeck M, Ghebremedhin E,
570 Englund E (2006) Cerebral amyloid angiopathy and cortical
571 microinfarcts as putative substrates of vascular dementia. *Int*
572 *J Geriatr Psychiatry* **21**, 681-687. 617
- 573 [11] van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb
574 AG, Blauw GJ, van der Flier WM, Scheltens P, Barkhof F,
575 van Buchem MA, van der Grond J (2014) Increased number
576 of microinfarcts in Alzheimer disease at 7-T MR imaging.
577 *Radiology* **270**, 205-211. 618
- 578 [12] van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, Spliet WG,
579 Hendrikse J, Luijten PR, Biessels GJ (2013) *In vivo* detec-
580 tion of cerebral cortical microinfarcts with high-resolution
581 7T MRI. *J Cereb Blood Flow Metab* **33**, 322-329. 619
- 582 [13] Ii Y, Maeda M, Kida H, Matsuo K, Shindo A, Taniguchi
583 A, Tomimoto H (2013) *In vivo* detection of cortical micro
584 infarcts on ultrahigh-field MRI. *J Neuroimaging* **23**, 28-32. 620
- 585 [14] Van Veluw SJ, Hilal S, Kuijf HJ, Ikram MK, Xin X, Yeow
586 TB, Venketasubramanian N, Biessels GJ, Chen C (2015)
587 Cortical microinfarcts on 3T MRI: Clinical correlates in
588 memory-clinic patients. *Alzheimers Dement* **11**, 1500-1509. 621
- 589 [15] van Dalen JW, Scuric EE, van Veluw SJ, Caan MW, Ned-
590 erveen AJ, Biessels GJ, van Gool WA, Richard E (2015)
591 Cortical microinfarcts detected *in vivo* on 3 Tesla MRI:
592 Clinical and radiological correlates. *Stroke* **46**, 255-257. 622
- 593 [16] McKhann G, Drachman D, Folstein M, Katzman R, Price D,
594 Stadlan EM (1984) Clinical diagnosis of Alzheimer's dis-
595 ease: Report of the NINCDS-ADRDA Work Group under the
596 auspices of Department of Health and Human Services
597 Task Force on Alzheimer's Disease. *Neurology* **34**, 939-944. 623
- 598 [17] Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL,
599 Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun
600 A, Hofman A, et al. (1993) Vascular dementia: Diagnostic
601 criteria for research studies: Report of the NINDSAIREN
602 International Workshop. *Neurology* **43**, 250-260. 624
- 603 [18] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L,
604 Wahlund LO, Nordberg A, Albert M, Almkvist O, Arai
605 H, Basun H, Blennow K, de Leon M, Decarli C, Erkin-
606 juntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A,
607 Ritchie K, Van Duijn C, Visser P, Petersen RC (2004) Mild
608 cognitive impairment- beyond controversies, towards a con-
609 sensus: Report of the International Working Group on Mild
610 Cognitive Impairment. *J Intern Med* **256**, 240-246. 625
- [19] McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT,
Feldman H, Cummings J, Duda JE, Lippa C, Perry EK,
Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa
D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz
CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J,
Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A,
Kosaka K, Lee VM, Lees A, Litvan I, Lodos E, Lopez OL,
Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska
EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ,
Yamada M (2005) Diagnosis and management of demen-
tia with Lewy bodies: Third report of the DLB Consortium.
Neurology **65**, 1863-1872. 626
- [20] Neary D, Snowden JS, Gustafson L, Passant U, Stuss D,
Black S, Freedman M, Kertesz A, Robert PH, Albert M,
Boone K, Miller BL, Cummings J, Benson DF (1998)
Frontotemporal lobar degeneration: A consensus on clinical
diagnostic criteria. *Neurology* **51**, 1546-1554. 627
- [21] Bruandet A, Richard F, Bombois S, Muraçca CA, Derame-
court V, Lebett F, Amouyel P, Paquier F (2009) Alzheimer's
disease with cerebrovascular disease and vascular dementia:
Clinical features and course compared with Alzheimer
disease. *J Neurol Neurosurg Psychiatry* **80**, 133-139. 628
- [22] Greenberg SM (1998) Cerebral amyloid angiopathy:
Prospects for clinical diagnosis and treatment. *Neurology*
51, 690-694. 629
- [23] Wattjes MP, Lutterbey GG, Gieseke J, Träber F, Klotz L,
Schmidt S, Schild HH (2007) Double inversion recovery
brain imaging at 3T: Diagnostic value in the detection of
multiple sclerosis lesions. *AJNR Am J Neuroradiol* **28**,
54-59. 630
- [24] Geurts JJ, Blezer EL, Vrenken H, van der Toorn A,
Castelijns JA, Polman CH, Pouwels PJ, Bö L, Barkhof F
(2008) Does high-field MR imaging improve cortical lesion
detection in multiple sclerosis? *J Neurol* **255**, 183-191. 631
- [25] Tallantyre EC, Morgan PS, Dixon JE, Al-Radaideh A,
Brookes MJ, Morris PG, Evangelou N (2010) 3 Tesla and
7 Tesla MRI of multiple sclerosis cortical lesions. *J Magn*
Reson Imaging **32**, 971-977. 632
- [26] Simon B, Schmidt S, Lukas C, Gieseke J, Träber F, Knol
DL, Willinek WA, Geurts JJ, Schild HH, Barkhof F, Wattjes
MP (2010) Improved *in vivo* detection of cortical lesions
in multiple sclerosis using double inversion recovery MR
imaging at 3 Tesla. *Eur Radiol* **20**, 1675-1683. 633
- [27] Raven JC (1995) *Coloured progressive matrices Sets A, Ab,*
B, Oxford Psychologists Press, New York. 634
- [28] Wilson B, Cockburn J, Baddeley A (1985) *The Rivermead*
Behavioural Memory Test, Thames Valley Test Company,
Edmunds. 635
- [29] Satoh M, Ogawa J, Tokita T, Nakaguchi N, Nakao K, Kida
H, Tomimoto H (2014) The effects of physical exercise with
music on cognitive function of elderly people: Mihama-
Kiho project. *PLoS One* **9**, e95230. 636
- [30] Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor
DA, Smith GD (2006) Serum cholesterol, haemorrhagic
stroke, ischaemic stroke, and myocardial infarction: Korean
national health system prospective cohort study. *BMJ*
333, 22. 637
- [31] Qiu C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir
MK, Sveinbjrnsdottir S, Eiriksdottir G, Klein R, Harris
TB, van Buchem MA, Gudnason V, Launer LJ (2010)
Cerebral microbleeds, retinopathy, and dementia: The
AGES-Reykjavik Study. *Neurology* **75**, 2221-2228. 638
- [32] Pettersen JA, Sathiyamoorthy G, Gao F-QQ, Szilagyi G,
Nadkarni NK, St George-Hyslop P, Rogaeva E, Black SE
(2008) Microbleed topography, leukoariosis, and cognition
639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675

- 676 in probable Alzheimer disease from the Sunnybrook demen- 719
677 tia study. *Arch Neurol* **65**, 790-795. 720
- 678 [33] Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin 721
679 GP, van der Lugt A, Breteler MM (2010) Prevalence and risk 722
680 factors of cerebral microbleeds: An update of the Rotterdam 723
681 scan study. *Stroke* **41**, 103-106. 724
- 682 [34] Poels MM, Ikram MA, van der Lugt A, Hofman A, 725
683 Niessen WJ, Krestin GP, Breteler MM, Vernooij MW (2012) 726
684 Cerebral microbleeds are associated with worse cognitive 727
685 function: The Rotterdam Scan Study. *Neurology* **78**, 326- 728
686 333. 729
- 687 [35] Patel B, Lawrence AJ, Chung AW, Rich P, Mackinnon 730
688 AD, Morris RG, Barrick TR, Markus HS (2013) Cerebral 731
689 microbleeds and cognition in patients with symptomatic 732
690 small vessel disease. *Stroke* **44**, 356-361. 733
- 691 [36] Gregoire SM, Smith K, Jäger HR, Benjamin M, Kallis 734
692 C, Brown MM, Cipolotti L, Werring DJ (2012) Cerebral 735
693 microbleeds and long-term cognitive outcome: Longitudinal 736
694 cohort study of stroke clinic patients. *Cerebrovasc Dis* 737
695 **33**, 430-435. 738
- 696 [37] Van Norden AG, van den Berg HA, de Laat KF, Gons RA, 739
697 van Dijk EJ, de Leeuw F-EE (2011) Frontal and temporal 740
698 microbleeds are related to cognitive function: The Radboud 741
699 University Nijmegen Diffusion Tensor and Magnetic Reso- 742
700 nance Cohort (RUN DMC) Study. *Stroke* **42**, 3382-3386. 743
- 701 [38] Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, 744
702 Schmidt R, Hartung HP (1999) Histopathologic analysis 745
703 of foci of signal loss on gradient-echo T2*-weighted MR 746
704 images in patients with spontaneous intracerebral hemor- 747
705 rhage: Evidence of microangiopathy-related microbleeds. 748
706 *AJNR Am J Neuroradiol* **20**, 637-642. 749
- 707 [39] Schrag M, McAuley G, Pomakian J, Jiffry A, Tung 750
708 S, Mueller C, Vinters HV, Haacke EM, Holshouser B, 751
709 Kido D, Kirsch WM (2010) Correlation of hypointensities 752
710 in susceptibility-weighted images to tissue histology 753
711 in dementia patients with cerebral amyloid angiopathy: A 754
712 postmortem MRI study. *Acta Neuropathol* **119**, 291-302. 755
- 713 [40] Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, 756
714 Schellenberg GD, Craft S, Leverenz JB, Montine TJ 757
715 (2007) Pathological correlates of dementia in a longitudinal, 758
716 population-based sample of aging. *Ann Neurol* **62**, 406-413. 759
- 717 [41] de Reuck J, Deramecourt V, Auger F, Durieux N, Cordon- 760
718 nier C, Devos D, Defebvre L, Moreau C, Caparros-Lefebvre 761
D, Bordet R, Mauraige CA, Pasquier F, Leys D (2014) 762
Post-mortem 7.0-tesla magnetic resonance study of cortical 763
microinfarcts in neurodegenerative diseases and vascular 764
dementia with neuropathological correlates. *J Neurol Sci* 765
346, 85-89. 766
- [42] Auriel E, Edlow BL, Reijmer YD, Fotiadis P, Ramirez- 767
Martinez S, Ni J, Reed AK, Vashkevich A, Schwab K, 768
Rosand J, Viswanathan A, Wu O, Gurol ME, Greenberg 769
SM (2014) Microinfarct disruption of white matter struc- 770
ture: A longitudinal diffusion tensor analysis. *Neurology* 771
83, 182-188. 772
- [43] Raman MR, Preboske GM, Przybelski SA, Gunter JL, 773
Senjem ML, Vemuri P, Murphy MC, Murray ME, Boeve BF, 774
Knopman DS, Petersen RC, Parisi JE, Dickson DW, Jack CR 775
Jr, Kantarci K (2014) Antemortem MRI findings associated 776
with microinfarcts at autopsy. *Neurology* **82**, 1951-1958. 777
- [44] Tomimoto H (2011) Subcortical vascular dementia. *Neu- 778
rosoci Res* **71**, 193-199. 779
- [45] Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, Kwak 780
KC, Yoon U, Lee JM, LEE JW, Shin JS, Kim CH, Noh Y, 781
Cho H, Kim HJ, Yoon CW, Oh SJ, Kim JS, Choe YS, Lee 782
KH, Lee JH, Ewers M, Weiner MW, Werring DJ, Na DL 783
(2013) Pathogenesis of cerebral microbleeds: *In vivo* imag- 784
ing of amyloid and subcortical ischemic small vessel disease 785
in 226 individuals with cognitive impairment. *Neurology* **73**, 786
584-593. 787
- [46] de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hof- 788
man A, Jolles J, Breteler MM (2000) Cerebral white matter 789
lesions and cognitive function: The Rotterdam Scan Study. 790
Ann Neurology **47**, 145-151. 791
- [47] Carey CL, Kramer JH, Josephson SA, Mungas D, Reed BR, 792
Schuff N, Weiner MW, Chui HC (2008) Subcortical lacunes 793
are associated with executive dysfunction in cognitively 794
normal elderly. *Stroke* **39**, 397-402. 795
- [48] Reijmer YD, Fotiadis P, Martinez-Ramirez S, Salat DH, 796
Schultz A, Shoamanesh A, Ayres AM, Vashkevich A, Rosas 797
D, Schwab K, Leemans A, Biessels GJ, Rosand J, John- 798
son KA, Viswanathan A, Gurol ME, Greenberg SM (2015) 799
Structural network alterations and neurological dysfunction 800
in cerebral amyloid angiopathy. *Brain* **138**, 179-188. 801
- [49] Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels 802
GJ (2012) Cerebral microinfarcts: A systematic review of 803
neuropathological studies. *J Cereb Blood Flow Metab* **32**, 804
425-436. 805